PMID- 26915878
OWN - NLM
STAT- MEDLINE
DCOM- 20161104
LR  - 20181202
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 48
IP  - 1
DP  - 2016 Jan-Feb
TI  - Light Chain Deposition Disease After Kidney Transplantation With Long Graft 
      Survival: Case Report.
PG  - 255-8
LID - S0041-1345(15)01178-1 [pii]
LID - 10.1016/j.transproceed.2015.12.009 [doi]
AB  - Light Chain Deposition Disease (LCDD) is a monoclonal immunoglobulin deposition 
      disease that commonly affects kidneys among other organs. It leads to end-stage 
      renal disease and has a high disease recurrence rate after kidney 
      transplantation. This has led some authors to advise against transplantation in 
      view of the poor long-term graft and patient outcomes. Recent literature has 
      shown improvement/stabilization of native kidney disease following the use of 
      bortezomib. We present 2 cases of LCDD after transplantation with graft 
      dysfunction. They were both treated with different therapeutic agents to induce 
      remission. Because sustained remission was not achieved they received bortezomib 
      following which they have experienced a prolonged period of stable renal function 
      with no clinically detectable disease. These unique cases highlight the 
      possibility to achieve long-term stable graft function and disease remission 
      after renal transplantation for LCDD.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Kuppachi, S
AU  - Kuppachi S
AD  - Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa 
      City, Iowa, USA. Electronic address: sarat-kuppachi@uiowa.edu.
FAU - Holanda, D
AU  - Holanda D
AD  - Department of Pathology, University of Iowa Hospitals and Clinics, Iowa City, 
      Iowa, USA.
FAU - Thomas, C P
AU  - Thomas CP
AD  - Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa 
      City, Iowa, USA; Department of Internal Medicine, VA Medical Center, Iowa City, 
      Iowa, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunoglobulin Light Chains)
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/therapeutic use
MH  - Bortezomib/therapeutic use
MH  - Graft Survival
MH  - Humans
MH  - *Immunoglobulin Light Chains
MH  - Kidney/physiopathology/surgery
MH  - Kidney Failure, Chronic/*complications/drug therapy
MH  - *Kidney Transplantation
MH  - Male
MH  - Middle Aged
MH  - Paraproteinemias/drug therapy/*etiology
MH  - *Postoperative Complications
MH  - Remission Induction/methods
MH  - Transplants/physiopathology
EDAT- 2016/02/27 06:00
MHDA- 2016/11/05 06:00
CRDT- 2016/02/27 06:00
PHST- 2015/11/10 00:00 [received]
PHST- 2015/12/07 00:00 [accepted]
PHST- 2016/02/27 06:00 [entrez]
PHST- 2016/02/27 06:00 [pubmed]
PHST- 2016/11/05 06:00 [medline]
AID - S0041-1345(15)01178-1 [pii]
AID - 10.1016/j.transproceed.2015.12.009 [doi]
PST - ppublish
SO  - Transplant Proc. 2016 Jan-Feb;48(1):255-8. doi: 
      10.1016/j.transproceed.2015.12.009.